Dietary patterns influence blood sugar and lipid control among type 2 diabetic patients in Taiwan – A pilot study

2016 ◽  
Vol 120 ◽  
pp. S120-S121
Author(s):  
Min-Su Tzeng ◽  
Yi-Cih Hong ◽  
Ching-Chu Chen ◽  
Chwen-Tzuei Chang ◽  
Mei-Due Yang ◽  
...  
2021 ◽  
Author(s):  
Damien Steciuk ◽  
Samia Mahmood Hafez Amir ◽  
Muzzammil Hosenally ◽  
Aroushini Goorapah

Abstract Background and Objectives: There is a need to re assess the value of low-GI food and its specific components. The effect of one of them, namely low-glycemic-index sugar, is unclear, as its impact is usually confounded when reported in the literature. This study attempts to breach this gap, shedding light on its effect in type 2 diabetic patients and evaluate if it could be considered as part of a dietary plan.Subjects and Methods: The blood sugar level of twenty (20) type 2 diabetics was monitored using a Continuous Glucose Monitoring system during two phases; firstly, an initial period of 5 days, whereby all the included patients were taking their usual dietary meals. Subjects were then randomized into two groups of equal size before embarking on a second phase; 10 subjects were instructed to eat prepared, portioned and delivered meals, the difference for the second group being that low-GI sugar was used for the preparation. Results: Compared to baseline (day 1), blood sugar dropped by 18% for the group with low-GI sugar and 13% for those who consumed sugar with a normal-GI. The variation in sugar levels was also more contained in the interventional group. A by-product of the study design shows that constant glucose monitoring could raise awareness, and may foster reduction in blood sugar levels. Portioned food was capable of reducing blood sugar levels, with elevated levels of compliance just after start. Conclusions: Even though the ultimate aim is to reduce sugar consumption by diabetic patients, the intake of a low-GI sugar seems to be less harmful than normal sugar. Compared to using normal sugar for the preparation of portioned foods, the use of a low-GI sugar is encouraged as part of a wider plan for the management of diabetic patients.


2016 ◽  
Vol 96 ◽  
pp. S62
Author(s):  
Ayse C. Hamamcioglu ◽  
Zehra Safi-Oz ◽  
Yasin Hazer ◽  
Dilek Arpaci ◽  
Furuzan Kokturk

2013 ◽  
Vol 6 (8) ◽  
pp. 859-864 ◽  
Author(s):  
Wilai Trakoon-osot ◽  
Uthai Sotanaphun ◽  
Pariya Phanachet ◽  
Supatra Porasuphatana ◽  
Umaporn Udomsubpayakul ◽  
...  

Medicine ◽  
2019 ◽  
Vol 98 (13) ◽  
pp. e14946 ◽  
Author(s):  
I-Wen Lin ◽  
Hao-Hsiang Chang ◽  
Yi-Hsuan Lee ◽  
Yi-Chun Wu ◽  
Chia-Wen Lu ◽  
...  

2020 ◽  
pp. 74-76
Author(s):  
R. Vijayarani ◽  
Tarunika. K. M

Type 2 diabetes mellitus is the most common form of diabetes mellitus characterized by hyperglycemia, insulin resistance, and relative insulin deficiency Dyslipidemia being common with diabetes, if we have a drug which can take care of both diabetes and Dyslipidemia, it will be more economical as well as increases the patient compliance. There are many studies on the effect of pioglitazone on triglyceride level. So this study was an attempt to find the effect of pioglitazone in diabetic patients with dyslipidemia in rural population. History taking and investigations were taken in 30 out patients visiting government sivagangai medical hospital between May 2019 and June 2019 The pre-treatment FBS mean was found to be 149.4+41.5 and the post treatment mean was found to be 98.2+27.3. Thus there is a significant reduction in fasting blood sugar level with p value less than 0.05. Serum triglycerides investigation pre treatment mean was found to be 181.5+18.2 and the post treatment mean is 160.07+21.03 .Thus there is a significant decrease of p<0.05 when pre and post treatment mean values were compared. The effect of pioglitazone on triglyceride level in type 2 diabetic patients was studied, it is evident that the Pioglitazone is both antidiabetic and antiatherogenic drug; we can conclude that the pioglitazone administration is effective to bring about significant change in the blood sugar, triglycerides. pioglitazone is a safe drug with less of side effects. , it will be more economical as well as increase patient compliance.


2019 ◽  
pp. 1-8
Author(s):  
Most. Zannatul Ferdous ◽  
M. A. Wahed ◽  
Zebunnesa Zeba

Aims: This study aimed to investigate the relationship between microalbuminuria and hypertension in type 2 diabetic patients. Study Design: It was a descriptive type of cross-sectional study. Place and Duration of Study: The study was conducted in collaboration at a diabetic clinic and Hypertension and Research Centre, Rangpur, Bangladesh from January to March 2018. Methodology: A total of 180 diabetic patients were selected purposively age ranges 30-75 years. Anthropometric as well as biochemical measurement was done. Data was collected by a semi-structured questionnaire through face to face interview and analyzed by SPSS-20. Results: Study subjects were separated into two groups. Group 1, those with normoalbuminuria (n=49) and Group 2, those having microalbuminuria (n=131). The prevalence of microalbuminuria was 72.8%. Group 2 or microalbuminuric patients showed higher blood pressure values (113.50±8.90 mm of Hg) as compared to Group 1 (101.88±9.80 mm of Hg). The results were statistically significant (P≤0.05). Further this study showed fasting blood sugar, duration of diabetes, systolic blood pressure and high level of sCreatinine were independently associated with microalbuminuria in the study subjects. The results were also statistically significant (P≤0.05). Conclusion: Our study revealed high prevalence of microalbuminuria in diabetic patients and has an optimistic association with blood pressure. This study suggests the need to screen for microalbuminuria early and the active management of modifiable risk factors in particular fasting blood sugar, sCreatinine, hypertension for intervention and prevention of further complications like end stage renal disease and cardiovascular diseases.


Sign in / Sign up

Export Citation Format

Share Document